{"disease":{"id":"pd-1-inhibitor","name":"pd 1 inhibitor"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06333561","title":"HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06631326","title":"HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)","phase":"","overall_status":"COMPLETED","enrollment_count":244,"lead_sponsor_name":"First Hospital of China Medical University","has_results":false},{"nct_id":"NCT06811844","title":"Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":208,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false},{"nct_id":"NCT05392413","title":"Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT05340270","title":"PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Guangxi Medical University","has_results":false},{"nct_id":"NCT07086300","title":"Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC","phase":"NA","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Kong Fanming","has_results":false},{"nct_id":"NCT07239661","title":"Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC","phase":"NA","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Kong Fanming","has_results":false},{"nct_id":"NCT06006650","title":"Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":114,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT06903858","title":"Neoadjuvant Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":105,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05549336","title":"Single-center, Prospective Cohort Study of PD-1 Inhibitors on Clinical Outcomes of Carotid Plaques in Tumor Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07531979","title":"Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":93,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT05498805","title":"PD-1 Inhibitors With or Without Radiation in Advanced Melanoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":92,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07359040","title":"Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05222035","title":"PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":68,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05520853","title":"SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":63,"lead_sponsor_name":"First People's Hospital of Hangzhou","has_results":false},{"nct_id":"NCT04611711","title":"Phase I/II Clinical Study of Decitabine Combined With TQB2450 Injection or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT06708650","title":"Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Guiping People's Hospital","has_results":false},{"nct_id":"NCT05520814","title":"PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Sichuan Cancer Hospital and Research Institute","has_results":false},{"nct_id":"NCT07133763","title":"Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"The Affiliated Hospital of Xuzhou Medical University","has_results":false},{"nct_id":"NCT05675033","title":"Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT04490421","title":"Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":45,"lead_sponsor_name":"Fuzhou General Hospital","has_results":false},{"nct_id":"NCT06871527","title":"Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":44,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT07394192","title":"Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-III Rectal Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":44,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT07067385","title":"Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT07125547","title":"Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT07233252","title":"Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT07126119","title":"Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT06809530","title":"Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":34,"lead_sponsor_name":"Guangzhou Medical University","has_results":false},{"nct_id":"NCT03683407","title":"Effect of Chemotherapy on TMB in NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Baodong Qin","has_results":false},{"nct_id":"NCT07133776","title":"Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"The Affiliated Hospital of Xuzhou Medical University","has_results":false},{"nct_id":"NCT05290194","title":"Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Fifth Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05222009","title":"G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":25,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06865521","title":"Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT05048017","title":"Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06195254","title":"Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT07312422","title":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Zhejiang Provincial People's Hospital","has_results":false},{"nct_id":"NCT05615142","title":"Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":9,"lead_sponsor_name":"Sichuan University","has_results":false}],"total":37},"guidelines":[],"source":"Drug Landscape verified database"}